What are you looking for?

by PMI Science | 10 Jul 2018

The 2018 Global Forum on Nicotine (GFN) provided a great opportunity for PMI delegates to share the latest clinical results with a unique setup of journalists, scientists, policymakers and major representatives of the tobacco industry. The presented results added important information about the risk-reduction potential of the Tobacco Heating System (THS or Platform 1).

 

Dr Christelle Haziza focused her talk on the changes in biological and functional markers after six months of switching to Platform 1, quitting smoking or continuing to smoke.

In-depth discussions continued by her poster about the studies on switching. A separate poster was dedicated to a similarly important branch of the assessment: smoking cessation.

Four additional ongoing themes of research were on display:

product experience and risk perceptions in Platform 1 users in Japan;

identifying factors that could predict the intention to use Platform 1;

assessing consumer responses to reduced risk products;

and modeling the population health impact of RRP introduction to Japan.

Detailed scientific brochures accompanied each poster.

PMI’s holographic installation illustrated the differences between cigarette smoke and the aerosol of Platform 1 throughout the second International Symposium on Nicotine Technology (ISoNTech). 

Related Articles

Disco-News-Iqos--Article-RET
News 

Independent data about Platform 1 – PMI at GFN

Disco-News-Conference2-Article
News 

Global Forum on Nicotine 2016

Our Library

Read our scientific publications and see the latest presentations on smoke-free products.

Platform 1 and Platform 4 were in the spotlight following the theme of the event: “new nicotine delivery systems backed by science and technology”. GFN and ISoNTech feature in PMI’s yearly calendar since sharing scientific evidence with a wider audience is one of the pillars of PMI’s commitment to transparency.

 

 

hologram

Our Scientists

Over 400 scientists and scientific experts collaborate on the development and assessment of our smoke-free products. We regularly present our results at scientific and regulatory conferences.

Meet our scientists

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced Risk Products (“RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.